Antibacterial Resistance Leadership Group 2.0: Back to Business-Reference-Cited by-同舟云学术

Antibacterial Resistance Leadership Group 2.0: Back to Business

Published:2021-02-15 Issue:4 Volume:73 Page:730-739
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Chambers Henry F¹,Evans Scott R²,Patel Robin³,Cross Heather R⁴,Harris Anthony D⁵,Doi Yohei⁶⁷,Boucher Helen W⁸,van Duin David⁹^ORCID,Tsalik Ephraim L¹⁰¹¹,Holland Thomas L⁴¹¹,Pettigrew Melinda M¹²,Tamma Pranita D¹³^ORCID,Hodges Kathryn R⁴,Souli Maria⁴,Fowler Vance G⁴¹¹

Affiliation:

1. Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, California, USA

2. Biostatistics Center, Department of Biostatics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Washington, D.C., USA

3. Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology; Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA

4. Duke Clinical Research Institute, Durham, North Carolina, USA

5. Department of Epidemiology and Public Health University of Maryland School of Medicine; Baltimore, Maryland, USA

6. Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

7. Department of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

8. Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts, USA

9. Division of Infectious Diseases, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA

10. Emergency Medicine Service, Durham VA Health Care System, Durham, North Carolina, USA

11. Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA

12. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA

13. Division of Infectious Diseases, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Abstract

Abstract In December 2019, the Antibacterial Resistance Leadership Group (ARLG) was awarded funding for another 7-year cycle to support a clinical research network on antibacterial resistance. ARLG 2.0 has 3 overarching research priorities: infections caused by antibiotic-resistant (AR) gram-negative bacteria, infections caused by AR gram-positive bacteria, and diagnostic tests to optimize use of antibiotics. To support the next generation of AR researchers, the ARLG offers 3 mentoring opportunities: the ARLG Fellowship, Early Stage Investigator seed grants, and the Trialists in Training Program. The purpose of this article is to update the scientific community on the progress made in the original funding period and to encourage submission of clinical research that addresses 1 or more of the research priority areas of ARLG 2.0.

Funder

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciab141/37408717/ciab141.pdf

Reference35 articles.

1. Antibacterial Resistance Leadership Group: open for business;Chambers;Clin Infect Dis,2014

2. The emperor’s new clothes: prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with methicillin-resistant Staphylococcus aureus bloodstream infections (PROVIDE);Lodise;Clin Infect Dis,2020

3. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists;Rybak;Am J Health Syst Pharm,2020